New concepts in treatment approaches and prognostic factors in aggressive NHL.
Shipp
Margaret
M
Dana-Farber Cancer Institute and Harvard Medical School, USA.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D020869:Gene Expression Profiling; D006801:Humans; D016393:Lymphoma, B-Cell / Q000145:classification / Q000188:drug therapy / Q000235:genetics; D008228:Lymphoma, Non-Hodgkin / Q000145:classification / Q000188:drug therapy* / Q000235:genetics; D016399:Lymphoma, T-Cell / Q000145:classification / Q000188:drug therapy / Q000235:genetics; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D000069283:Rituximab; D014750:Vincristine / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone